The FTC's 2022 Health Products Compliance Guidance changed the substantiation landscape for health-related product claims in a way many brands have not yet fully absorbed. Where the previous 1998 guidance described randomized controlled trials as the "most reliable" form of evidence, the 2022 update states that "as a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing." Animal and in vitro studies, it adds explicitly, "may provide useful supporting or background information" but cannot on their own substantiate health-related claims.
That shift matters practically. A brand using a cell study or an animal study to support a direct efficacy claim is not in a position of questionable strategy. It is in a position of documented non-compliance with the FTC's current standard. And yet the assumption that any positive study supports a product claim remains common across marketing, product development, and even some regulatory teams.
Not all studies provide the same level of evidence. The type of research, the methodology, the population, the outcomes measured, and the conditions under which the study was conducted all determine where a study sits in the evidence hierarchy, and that position determines what can be claimed.
The evidence hierarchy has direct implications for claim language. A 2025 peer-reviewed analysis published in PubMed on validation of "clinically proven" claims maps the required evidence pathway: preclinical research informs mechanism understanding, pilot studies assess feasibility, RCTs establish efficacy and safety, and multicentric or longitudinal studies confirm reproducibility. Each stage contributes to the evidence base without substituting for the others.
For product claim development, this hierarchy translates into a practical language scale:
Selecting the right study is the first step in creating defensible claims. The seven factors below determine whether any given study supports a claim, and at what level.
Study design is the single most important determinant of evidence strength for use in a study for product claims. Four design categories matter for claim development:
A study on an isolated ingredient is not automatically relevant to a finished product containing that ingredient. The FTC's 2022 guidance addresses this directly, noting that a "clinically tested ingredient" claim on a product "implies not only that the ingredient has a benefit but also that the product containing the ingredient confers that benefit." For combination products, ingredient-level evidence may be insufficient without product-specific testing.
Three relevance questions to answer:
If any of these questions reveal a meaningful mismatch, the study's direct relevance to the product claim is limited.
For a fuller treatment of how ingredient claims work alongside packaging and label requirements, our guide on how to verify food ad ingredient claims effectively covers the verification process.
The study population defines who the claim applies to. A study conducted in older adults with a specific health condition cannot directly support a claim targeting the general adult population. A study conducted exclusively in men does not provide evidence applicable to women without additional research.
Key population factors to check:
When the study population differs materially from the intended consumer, the claim must either be qualified to reflect the studied population or additional research must support the broader claim.
Sample size affects how reliably study results represent what would happen in the broader population. Studies are designed with a target sample size calculated to have adequate "statistical power," meaning a reasonable probability of detecting a real effect if one exists.
Practical implications for claim evaluation:
Endpoints define what the study actually measured. A study's results can only support claims about the outcomes it measured, not outcomes assumed to follow from those measurements.
Primary endpoints are the main outcomes the study was designed and powered to detect. These provide the strongest basis for claims. If a primary endpoint was not met, secondary results cannot rescue the study as the foundation for a strong efficacy claim.
Secondary endpoints are additional measurements. They may support supplementary claims with qualified language, but they require more cautious wording than primary outcomes.
Biomarker vs consumer outcome distinction: A biomarker is a measured biological indicator. A consumer outcome is something a person experiences. A study showing improvement in a specific biomarker does not automatically support a claim about the experience associated with that biomarker. The step from biomarker change to consumer benefit requires either direct measurement of the experience or a well-established and scientifically accepted link between the biomarker and the claimed outcome.
A study produces results under specific conditions. Claims derived from the study are only supported under those same conditions, or conditions reasonably analogous to them.
Dosage: If the study tested 500mg of an ingredient and the product contains 250mg, the product delivers half the studied dose. The claim's validity for the product dose requires either dose-response evidence or more qualified language.
Duration: A four-week study demonstrates a four-week effect. Claims implying sustained or long-term benefit from a short-duration study go beyond what was demonstrated.
Delivery format: Bioavailability varies between capsules, beverages, powders, and topical formats. An ingredient tested orally does not automatically support topical claims. Format-specific research is the appropriate basis for format-specific claims.
For background on how labeling requirements interact with the specific conditions of product use, our overview of regulatory compliance in FMCG packaging covers how product conditions affect label requirements across categories.
Publication status and study transparency affect how much confidence the evidence warrants. Key indicators:
The table below synthesizes the seven factors into a practical reference for claim development teams.
The strongest wording requires the strongest evidence. Using high-confidence language for lower-tier evidence is the most common substantiation failure in health product marketing, and the one most likely to attract FTC attention under the 2022 guidance.
For more on how the full claim substantiation process works from evidence through approved language, our step-by-step guide on how to build science-backed product claims covers the complete framework.
Evaluating seven quality factors across multiple studies for a growing product range is a process that scales poorly when done entirely manually. AI-assisted review tools address this by integrating claim language checks and evidence gap identification into the workflow.
Practical applications include organizing study information by evidence tier, comparing proposed claim wording against the quality factors of the supporting evidence, flagging language that implies a confidence level the evidence does not support, and maintaining version-controlled documentation that links every approved claim to its evidence source.
GetGenAI's compliance review platform connects through API, MCP server, or AI assistant skills, allowing teams to run automated checks against current regulatory requirements at each design milestone.
The seven factors covered in this article - study design, product relevance, study population, sample size and power, endpoints, dosage and conditions, and publication quality - together determine what a study can and cannot support as the basis for a consumer-facing claim.
The discipline is not finding the most positive study available. It is accurately assessing what any given study demonstrates, and choosing claim language that reflects that assessment precisely.
Brands that apply this evaluation systematically before claim development begins create marketing that is both more credible to consumers and more defensible in regulatory review. The evidence hierarchy is not a constraint on marketing effectiveness. It is the framework that makes marketing claims last.
Moving from complex clinical research to bulletproof product claims doesn't have to be a manual bottleneck. Try GetGenAI Now to automate study evaluations, bridge language gaps, and ensure your marketing claims are 100% regulatory-compliant.
Can a brand make a product claim using only one clinical study?
Yes, if the study is well-designed, adequately powered, and directly relevant to the product and consumer. A single well-designed RCT can support "shown in a clinical study to" or "demonstrated in a human study to" language. It cannot support "clinically proven" language, which implies multiple consistent studies, or absolute outcome claims. The FTC's 2022 guidance indicates that for health-related benefits, RCT evidence is now generally required, but a single strong study can meet that threshold with appropriately qualified wording.
Are published studies always stronger evidence than unpublished research?
Peer-reviewed publication is a quality signal because independent experts have evaluated the methodology and results. However, publication bias, the tendency for positive results to be published more often than negative or null results, means that the published literature does not represent a neutral sample of all research conducted. Unpublished company studies conducted under rigorous protocols can also provide substantiation. The quality of the study design and methodology matters more than publication status alone.
What should brands do when a study has positive results but important limitations?
Use the evidence at the claim level the limitations support, not the level the positive result alone might suggest. If the study had a small sample, qualify the claim with "shown in a preliminary study." If the study population was narrow, restrict the claim to the studied population. Document the limitations in the substantiation file and note the claim wording decisions made in response to them. This demonstrates good-faith compliance effort and creates a clear record if the claim is ever challenged.
Get intels on brand, platform, and regulatory changes, distilled by our compliance team
